Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PRE · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Prenetics Global (PRE) · oqro.io/stocks/PRE · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$8.80−1.51 (−14.65%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−31.7% (−$4.08) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $12.88 on Nov 20, 2025 to $8.80 on Nov 20, 2026 (−31.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Quarry Bay, Hong Kong. Foreign private issuer: reports on Form 20-F or 40-F.
Pharmaceutical Preparations company based in Quarry Bay, Hong Kong. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−31.7%
Market value
$148M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 507K shares sold short (3.0% of shares outstanding), −1.5% vs the previous count, 2.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of Prenetics Global is on record in SEC filings since 2006.
No open-market sale by an insider of Prenetics Global (PRE) was filed with the SEC in the last 90 days.
No trade in Prenetics Global (PRE) was disclosed by a member of Congress in the last 12 months.
Prenetics Global's next results are expected on Feb 16, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Off-exchange trading: 44.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (28.7% on ATS, 15.4% with other brokers), above its 26-week average of 39.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: SIGMA X2 (17.9%), INSTINCT X (15.7%), UBS ATS (14.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Last results
—
Next results, expected
Feb 16, 2027
Purchases after results
Not enough history
From Prenetics Global's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Prenetics Global's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Records
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Apr 30, 2026. Read the filing
+1327% on the year before ($5.57M)
+25% on the year before ($10.4M)
+16156% on the year before ($370K)
+271% on the year before ($5.2M)
+25% on the year before ($10.4M)
+1158% on the year before ($5.51M)
+121% on the year before ($10.4M)
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 11,000 words.
We are a consumer health company advancing human health and longevity through science-backed products, global brand partnerships, and AI-driven operations. Our flagship consumer health brand, IM8—co-founded with David Beckham—generated $60.1 million in revenue in its first full fiscal year, achieved $120 million in ARR as of December 2025, and ships to more than 30 countries. We also operate a consumer genetic testing brand in CircleDNA leveraging next-generation sequencing technology to deliver over 500 personalized reports across 20+ categories. Since its global launch in November 2019, CircleDNA has delivered more than 500,000 test kits across 30+ countries. We view IM8 and CircleDNA as complementary assets.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Apr 30, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
No Schedule 13D or 13G filing on PRE over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, PRE is down 28.5% and the index fund is up 4.5%: 33 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much PRE moves
Beta 1.8 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Latest annual report filed Apr 30, 2026, compared with the one filed Apr 30, 2025. Read the filing
Source: SEC EDGAR, Form 20-F filed Apr 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.